Form 4: Instil Bio Director George Matcham Acquires 5,000 Stock Options

Director George Matcham of Instil Bio, Inc. reports the acquisition of 5,000 stock options with an exercise price of $10.50 on June 13, 2024.

Summary

• On June 13, 2024, George Matcham, a director of Instil Bio, Inc., acquired 5,000 stock options.
• The exercise price of these options is $10.50.
• The options vest in 12 equal monthly installments starting July 13, 2024, contingent upon continuous service.
• Any unvested portion will fully vest at the next annual stockholder meeting, also subject to continuous service.
• Full vesting also occurs upon death, disability, or a change in control.
• The options expire on June 12, 2034.
• Following the transaction, Matcham directly owns 5,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction. The acquisition of stock options by a director is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule is contingent upon continuous service, suggesting an incentive for the director to remain with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of stock options by a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates